Business Context and Reporting Period
This Form 8-K is a current report filed by Inmune Bio, Inc. on April 4, 2022. The company is an emerging growth company incorporated in Nevada, with principal executive offices in La Jolla, California. The filing primarily addresses a scientific event rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement filing (such as a 10-K or 10-Q) and contains no quantitative financial data.
Material Changes
There are no material financial changes reported in this document. The significant event reported is the issuance of a press release on April 4, 2022, highlighting key findings from the "NK Cells in Solid Tumors" workshop. Dr. Mark Lowdell, the Company's Chief Scientific Officer, led this workshop during the Innate Killer Summit held in San Diego from March 30 to April 1, 2022.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors. The content is limited to the announcement of the scientific workshop and the attachment of the corresponding press release as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific scientific findings regarding NK cells in solid tumors.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Consult the most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains none.
- Confirm the role of Dr. Mark Lowdell as Chief Scientific Officer in the context of the company's R&D pipeline.